

IPM oral presentations

Sun., Oct. 21, 14:00-17:00, Burdeos

Satellite Session: Planning for Success: Next Steps for Dapivirine Ring
Co-hosted by OPTIONS, IPM

IPM-authored poster presentations

All posters will be exhibited in the Poster Hall from Tues., Oct. 23 to Thurs., Oct. 25. Authors will be present to answer questions on the designated dates below.

Tues., Oct. 23, 17:30-19:30, Poster Hall, Poster Session 01

Dapivirine ring

- P21.05. Pharmacokinetics of Dapivirine Vaginal Ring During Ring Removals and Re-insertions

DS003-based products

- P09.13. Formulation Development of a Commingled Dapivirine-DS003 Intravaginal Ring for the Concurrent Delivery of Two Microbicides
- P09.15. Compatibility Screening for Excipients for Delivery of Dapivirine and DS003 Concurrently From an Intravaginal Ring

Weds., Oct. 24, 17:30-19:30, Poster Hall, Poster Session 02

Dapivirine ring

- P12.02. Roll-over: Experience of Switching Participants to Active Treatment Arm During a Phase III Placebo-controlled Trial
- P19.48LB. HIV-1 Incidence, Adherence to Ring Use and Safety in an Open-label Trial of Dapivirine Vaginal Ring – DREAM
- P21.06. Pharmacokinetics (PK) of Dapivirine Vaginal Ring (25 mg) Co-administered With Clotrimazole

DS003-based products

- P05.08. Safety and Pharmacokinetics of DS003 When Administered to Women as a Vaginal Tablet
- P09.14. Formulation Development of a Segmented Intravaginal Ring for the Concurrent Delivery of Dapivirine and DS003
- P21.02. Pharmacodynamic Activity of DS003, a Novel gp120 Blocker, When Administered to Women as a Vaginal Tablet
- P24.06. Pharmacokinetic Comparison of DS003, a Novel gp120 Blocker, Delivered by Vaginal Tablet or Vaginal Ring in Pigtailed Macaques

Darunavir-based products

- P09.16. Compatibility Screening for Excipients for Delivery of Dapivirine and Darunavir Concurrently From an Intravaginal Ring

IPM-supported oral presentations

Tues., Oct. 23, 13:15-13:30, Londres

Oral Abstract Session: If I Choose, Will I Use? Products, People and Preferences

OA05.02. Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data from The Ring Study (IPM 027) (*MatCH*)

Weds., Oct. 24, 13:00-14:30, Londres

Oral Abstract Session: Contraception and HIV Risk: Still Between a Rock and a Hard Place

- OA12.02LB. Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy (*Microbicide Trials Network [MTN]*) (13.15-13:30)
- OA12.06. Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study (*MTN*) (14.15-14:30)

Thurs., Oct. 25, 09:00-09:15, Oxford

Oral Abstract Session: Opinion 360: Meaningful Engagement from Research to Roll Out

OA18.03. Ethical Considerations for Involving Adolescents Aged 16-17 in HIV Prevention Clinical Trials: Community Perspectives from Uganda (*MTN*)

Thurs., Oct. 25, 10:45-11:00, Marsella, Burdeos & Estrasburgo

Oral Abstract Session: Great Expectations: The Impact of PrEP

OA23.02. Sensitive Next-Generation Sequencing of HIV-1 from Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study (*MTN*)

Thurs., Oct. 25, 11:45-12:00, Londres

Oral Abstract Session: Into the Future with Delivery Technologies

OA20.06. The dapivirine and levonorgestrel MPT ring: understanding the levonorgestrel binding reaction with silicone elastomer (*Queen's University Belfast [QUB]*)

IPM-supported poster presentations

All posters will be exhibited in the Poster Hall from Tues., Oct. 23 to Thurs., Oct. 25. Authors will be present to answer questions on the designated dates below.

Tues., Oct. 23, 17:30-19:30, Poster Hall, Poster Session 01

Dapivirine ring

- P03.11. Site Approaches to Working with Participant Concerns Regarding Hair Collection: Kampala Site Experience in MTN025/HOPE (*MTN*)
- P03.13. Does the Use of the Dapivirine Vaginal Ring Result in Change in Risk Sexual Behavior? (*MRC Uganda*)
- P03.53. Acceptability and Feasibility of CHARISMA: Results of a Pilot Study Addressing Relationship Dynamics, Intimate Partner Violence and Microbicide Use (*CHARISMA*)
- P05.03. Characteristics of Women Who Enrolled Into an Open Label Extension Trial of the Dapivirine Intravaginal Ring for HIV-1 Prevention (*MTN*)
- P05.09. Potential Causes for Decreased Enrollment of Acutely Infected Participants in the ASPIRE Trial Compared to VOICE (*MTN*)
- P06.07. Benefits of Prescreening Workshops on Participants' Understanding of CHOICE, ADHERENCE and OPEN REPORTING in MTN-025 Study: Kampala Site Experience (*MTN*)
- P06.13. Motivators for Participation in an Open Label Extension Microbicide Trial in South Western Uganda (*MRC Uganda*)

- P06.25. Examining the Relationship Between Multiple Sexual Partners and Adherence to the Dapivirine Vaginal Ring in a Trial in South Western Uganda (*MRC Uganda*)
- P07.13. Pregnancy Incidence and Outcomes Among Women Using Dapivirine Vaginal Ring for HIV Prevention in a Phase III Clinical Trial in South Western Uganda (*MRC Uganda*)
- P09.05. Impact of Intermittent Use on In Vitro Release and Residual Content of 25 mg Dapivirine Rings (*QUB*)
- P09.07. Impact of Particle Size and Release Testing Media on Release of Dapivirine From a Silicone Elastomer Vaginal Ring (*QUB*)
- P09.09. Embracing Medidata Rave in the 21st Century: Tips for Successful Implementation (*MTN*)
- P09.19. Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive Manufacturing (*QUB*)
- P11.01. Risk Factors for HIV-1 Acquisition Among 18-21 Year Old South African Women Participating in an HIV Prevention Trial (*MTN*)
- P14.07. Ensuring Potential Volunteers Are the “Right Fit” for Study Participation: Insights From the CAPRISA eThekweni Clinical Research Site (*MTN*)
- P14.13. Fidelity Monitoring to Ensure Accurate Implementation of an Evidence-based Adherence Counseling Intervention in MTN-025 (the HOPE Study) (*MTN*)
- P14.33. Measuring HEART: Validity of a HEALThy Relationships Assessment Tool to Guide Tailored Counseling in the CHARISMA Pilot Study (*CHARISMA*)
- P16.09. Evaluating the Potential Impact and Cost-effectiveness of Dapivirine Ring Pre-exposure Prophylaxis for HIV Prevention (*OPTIONS*)
- P24.01. Comparison of Dissolution Testing Methods for the 25 mg Dapivirine Vaginal Ring (*QUB*)
- P25.03. From Theory to Practice: Implementation of Client Centered Adherence Counselling at the Kampala Site for the HOPE Study (*MTN*)

Dapivirine-contraceptive ring

- P06.09. Need for a Multi-purpose Dapivirine Vaginal Ring to Address Sexual and Reproductive Health Challenges: Lessons Learnt from South Western Uganda (*MRC Uganda*)

Weds., Oct. 24, 17:30-19:30, Poster Hall, Poster Session 02

Dapivirine ring

- P09.06. Mechanical Testing Protocols for Vaginal Ring Formulations (*QUB*)
- P06.06. Innovative Approaches for Effective Recruitment of Former Trial Participants Into MTN 025/HOPE Open Label Trial; How Kampala Team Did It!" (*MTN*)
- P06.10. Effective Community Engagement in HIV Prevention Trials: Experience from a Microbicide Trial in South-Western Uganda (*MRC Uganda*)
- P07.10. Dapivirine Vaginal Ring Use and Cervical Cytology Abnormalities: Data From the Placebo-controlled MTN-020/ASPIRE Trial (*MTN*)
- P09.08. Effect of Exposure of the 25 mg Dapivirine Vaginal Ring to Cleaning Solutions and Personal Lubricants (*QUB*)
- P17.02. Impact of the 25 mg Dapivirine and Placebo Vaginal Rings on the Vaginal Microbiota of Adolescents, Lactating and Post-menopausal Women (*MTN*)
- P23.04. Planning for Dapivirine Ring Introduction: Summarizing Lessons Learned from Like-product Experiences (*OPTIONS*)

- P25.06. Empowering Trial Participants to Use the Dapivirine Vaginal Ring: Experience from an Open Label Extension Trial in South Western Uganda (*MRC Uganda*)
- P25.08. Sharing Residual Drug Levels With Trial Participants: Experience From an Open Label Extension Microbicide Trial in South Western Uganda (*MRC Uganda*)

Dapivirine ring and dapivirine-contraceptive ring

- P09.06. Mechanical Testing Protocols for Vaginal Ring Formulations (*QUB*)